dipk1a Antibody

What is DIPK1A and why is it significant for research?

DIPK1A (Divergent Protein Kinase Domain 1A) is a protein with a canonical length of 428 amino acid residues and a molecular mass of approximately 49 kDa in humans . It belongs to the DIPK protein family and is primarily localized in the endoplasmic reticulum (ER) . The protein is widely expressed across diverse tissue types, suggesting fundamental cellular functions . DIPK1A is also known by synonyms including Family with Sequence Similarity 69 Member A (FAM69A) and FLJ23493 . Orthologs have been identified in multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken , making it an evolutionarily conserved protein worthy of investigation across various model organisms.

What types of DIPK1A antibodies are available for research applications?

DIPK1A antibodies are available in both polyclonal and monoclonal formats from multiple suppliers . These antibodies have been developed against various epitopes within the protein, including specific amino acid regions such as AA 49-162 . According to Antibodypedia, there are approximately 47 different DIPK1A antibodies available from 11 different providers . The diversity of available antibodies allows researchers to select reagents optimized for specific applications including Western blotting (WB), ELISA, immunocytochemistry (ICC), and immunohistochemistry (IHC) .

How should I select the appropriate DIPK1A antibody for my experiment?

When selecting a DIPK1A antibody, consider the following criteria:

• Application compatibility: Verify that the antibody has been validated for your intended application (WB, ELISA, ICC, IHC)

• Species reactivity: Ensure the antibody recognizes DIPK1A in your species of interest (human, mouse, zebrafish, etc.)

• Antibody format: Consider whether polyclonal or monoclonal antibodies are better suited for your research needs:

  • Polyclonal antibodies generally provide higher sensitivity by recognizing multiple epitopes

  • Monoclonal antibodies offer greater specificity and consistency

• Epitope location: Consider which domain or region of DIPK1A you wish to target, especially if studying specific isoforms

• Validation data: Review available data demonstrating antibody specificity and performance in applications similar to yours

What are the standard protocols for using DIPK1A antibodies in Western blotting?

For optimal Western blot detection of DIPK1A:

• Sample preparation:

  • Use RIPA or NP-40 based buffers containing protease inhibitors

  • Include phosphatase inhibitors if studying phosphorylation states

• Gel electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels to effectively resolve the 49 kDa DIPK1A protein

  • Transfer to PVDF or nitrocellulose membranes using standard conditions

• Antibody incubation:

  • Block with 5% non-fat dry milk or BSA in TBST

  • Dilute primary antibodies 1:1000-1:5000 as recommended

  • Incubate overnight at 4°C or 2 hours at room temperature

  • Use appropriate HRP-conjugated secondary antibodies

• Detection:

  • Expect to visualize a band at approximately 49 kDa for the canonical form

  • Consider longer exposure times if expression is low in your sample type

What controls should I include when working with DIPK1A antibodies?

Proper experimental controls are essential for interpreting results with DIPK1A antibodies:

• Positive controls:

  • Cell lines or tissues known to express DIPK1A (note its wide tissue distribution)

  • Recombinant DIPK1A protein when available

• Negative controls:

  • Samples with DIPK1A knockdown/knockout (if available)

  • Isotype control antibodies to detect non-specific binding

  • Secondary antibody-only controls to assess background

• Specificity controls:

  • Blocking peptide competition assays where the immunizing peptide is pre-incubated with the antibody

  • Multiple antibodies targeting different epitopes to confirm specificity

How can I validate the specificity of a DIPK1A antibody for my particular experimental system?

Comprehensive validation strategies include:

• Genetic approaches:

  • Compare samples with and without DIPK1A expression (knockout/knockdown)

  • Overexpression systems with tagged DIPK1A to confirm antibody detection

• Biochemical approaches:

  • Peptide competition assays with the immunizing peptide

  • Immunoprecipitation followed by mass spectrometry identification

  • Western blot analysis under reducing and non-reducing conditions

• Orthogonal techniques:

  • Correlation of protein detection with mRNA expression

  • Comparison of results from multiple antibodies targeting different epitopes

  • Subcellular localization consistency with known ER distribution

What considerations are important for studying DIPK1A isoforms?

Up to two different isoforms have been reported for DIPK1A , requiring careful experimental design:

• Antibody selection:

  • Verify that your antibody's epitope is present in all isoforms of interest

  • Consider using isoform-specific antibodies if available

• Detection strategy:

  • Use higher resolution SDS-PAGE to separate similar-sized isoforms

  • Consider 2D gel electrophoresis for isoforms with similar molecular weights but different isoelectric points

• Complementary approaches:

  • Combine protein detection with RT-PCR for isoform-specific mRNA expression

  • Use mass spectrometry to identify unique peptides from different isoforms

• Data reporting:

  • Clearly specify which isoform(s) are detected in your experimental system

How can I optimize immunohistochemistry and immunocytochemistry protocols for DIPK1A detection?

For effective immunostaining of DIPK1A in tissues and cells:

• Fixation optimization:

  • Test different fixatives (paraformaldehyde, methanol, acetone) as epitope accessibility may vary

  • Determine optimal fixation duration to preserve antigenicity

• Antigen retrieval:

  • Evaluate both heat-induced epitope retrieval (citrate buffer, pH 6.0 or EDTA buffer, pH 9.0)

  • Consider enzymatic retrieval methods if heat-based methods are unsuccessful

• Antibody conditions:

  • Test various dilutions, typically starting at 1:100-1:500 for IHC/ICC applications

  • Optimize incubation time and temperature (overnight at 4°C typically yields best results)

• Detection systems:

  • Compare direct and indirect detection methods

  • For fluorescence, select secondary antibodies with appropriate spectral properties

  • For chromogenic detection, optimize substrate development time

What approaches are recommended for studying DIPK1A protein interactions?

To investigate DIPK1A interacting partners:

• Co-immunoprecipitation:

  • Use DIPK1A antibodies to pull down protein complexes

  • Identify interacting proteins via Western blot or mass spectrometry

  • Consider crosslinking approaches to stabilize transient interactions

• Proximity labeling methods:

  • Fuse DIPK1A to BioID or APEX2 for proximal protein labeling

  • Identify labeled proteins using streptavidin pulldown followed by mass spectrometry

• Fluorescence-based interaction studies:

  • FRET or BiFC to visualize protein interactions in living cells

  • Co-localization studies with confocal microscopy

  • FLIM (Fluorescence Lifetime Imaging Microscopy) for quantitative interaction analysis

How can I study post-translational modifications of DIPK1A?

For investigating DIPK1A modifications:

• Modification-specific detection:

  • Use phospho-specific antibodies if available

  • Employ antibodies against other modifications (glycosylation, ubiquitination)

• Enrichment strategies:

  • Phosphopeptide enrichment prior to mass spectrometry

  • Immunoprecipitation with modification-specific antibodies

• Functional analysis:

  • Compare wild-type and mutant DIPK1A (with modified sites mutated)

  • Assess effects of kinase/phosphatase inhibitors on DIPK1A modification status

What methods are recommended for quantitative analysis of DIPK1A expression?

For accurate quantification of DIPK1A levels:

• Western blot quantification:

  • Use appropriate loading controls (GAPDH, β-actin)

  • Implement standard curves with recombinant DIPK1A

  • Use imaging systems with linear detection range

• ELISA-based quantification:

  • Consider sandwich ELISA using antibodies recognizing different epitopes

  • Include standard curves with recombinant protein

• Statistical considerations:

  • Normalize to total protein or housekeeping proteins

  • Process all samples simultaneously to minimize technical variation

  • Apply appropriate statistical tests based on experimental design

What are common issues when working with DIPK1A antibodies and how can they be resolved?

How can I optimize subcellular fractionation experiments for DIPK1A detection?

Since DIPK1A is primarily localized to the ER , consider these optimization strategies:

• Fractionation protocols:

  • Use differential centrifugation to separate major cellular components

  • For ER enrichment, consider sucrose density gradient centrifugation

  • Commercial fractionation kits may provide consistent results

• Quality control:

  • Verify fraction purity using established markers (e.g., Calnexin for ER, GAPDH for cytosol)

  • Assess cross-contamination between fractions

• Detection strategy:

  • Western blot analysis of fractions using optimized antibody dilutions

  • Consider concentration steps if DIPK1A expression is low

How do storage conditions affect DIPK1A antibody performance?

Proper storage is critical for maintaining antibody activity:

• Long-term storage:

  • Store antibodies at -20°C to -80°C according to manufacturer recommendations

  • Avoid repeated freeze-thaw cycles by preparing small aliquots

• Working solutions:

  • Store at 2-8°C for short periods (typically 1 month)

  • Add preservatives like sodium azide (0.02-0.05%) to prevent microbial growth

• Stability considerations:

  • Monitor for signs of degradation (loss of activity, increased background)

  • Validate antibody performance periodically against known positive controls

  • Consider refreshing antibody stocks for critical experiments